Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 42.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 11,596 shares of the biopharmaceutical company’s stock after selling 8,612 shares during the period. Martingale Asset Management L P’s holdings in Regeneron Pharmaceuticals were worth $7,355,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of REGN. GAMMA Investing LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after buying an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after buying an additional 810,144 shares during the period. Nuveen LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $343,764,000. Pacer Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after buying an additional 390,374 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock valued at $305,311,000 after buying an additional 303,785 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the subject of several research reports. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price target for the company. Morgan Stanley reissued an “overweight” rating and set a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Canaccord Genuity Group reissued a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Finally, Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $829.65.

Regeneron Pharmaceuticals Trading Up 1.2%

Regeneron Pharmaceuticals stock opened at $598.16 on Friday. The firm has a 50-day moving average price of $549.27 and a two-hundred day moving average price of $592.95. The firm has a market capitalization of $63.40 billion, a price-to-earnings ratio of 15.07, a PEG ratio of 1.97 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The company had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $11.56 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.